404-26-2

Basic information

• Product Name: CHEMBRDG-BB 5276151
• Synonyms: CHEMBRDG-BB 5276151;4-[(trifluoroacetyl)amino]benzoic acid;4-(2,2,2-trifluoroethanoylamino)benzoic acid;4-[(2,2,2-trifluoroacetyl)amino]benzoic acid;4-[(trifluoroacetyl)amino]benzoic acid(SALTDATA: FREE);NSC 150503;p-(TrifluoroacetaMido)benzoic Acid
• CAS NO: 404-26-2
• Molecular Formula: C₉H₆F₃NO₃
• Molecular Weight: 233.15
• Product Categories: Aromatics;Intermediates
• Mol File: 404-26-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 370°Cat760mmHg
• Flash Point: 177.5°C
• Appearance: /
• Density: 1.539g/cm³
• Vapor Pressure: 3.98E-06mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: Refrigerator
• Solubility: Methanol
• CAS DataBase Reference: CHEMBRDG-BB 5276151(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 5276151(404-26-2)
• EPA Substance Registry System: CHEMBRDG-BB 5276151(404-26-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 404-26-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Intermediate in the production of Folic Acid

InChI:InChI=1/C9H6F3NO3/c10-9(11,12)8(16)13-6-3-1-5(2-4-6)7(14)15/h1-4H,(H,13,16)(H,14,15)

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 76-05-1 trifluoroacetic acid 
• 56-91-7 p-aminomethylbenzoic acid 
• 407-25-0 trifluoroacetic anhydride 
• 540-37-4 p-aminoiodobenzene 
• 124-38-9 carbon dioxide 
• 126063-08-9 2,2,2-trifluoro-N-(4-iodophenyl)acetamide 
• 383-64-2 S-ethyl trifluoroacetate 

Downstream Products

• 457-52-3 4-(2,2,2-trifluoro-acetylamino)-benzoyl chloride 
• 233600-78-7 dimethyl p-trifluoroacetamidobenzoyl-L-glutamate 
• 233600-89-0 <3',3',4',4'-(2)H4>-p-aminobenzoyl-L-glutamic acid 
• 233600-88-9 <3',3',4',4'-(2)H4>-dimethyl p-trifluoroacetamidobenzoyl-L-glutamate 
• 150-13-0 4-amino-benzoic acid 
• 304646-56-8 methyl 4-(2,2,2-trifluoroacetamido)benzoate 
• 956427-79-5 tert-butyl (2-(4-aminobenzamido)-4-(thiophen-2-yl)phenyl)carbamate 

Relevant articles and documents

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study

Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In?vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.

Discovery of multi-target anticancer agents based on HDAC inhibitor MS-275 and 5-FU

Histone deacetylases (HDACs) inhibitors have multiple effects targeting the cancer cells and have become one of the promising cancer therapeutics with possibly broad applicability. Combination of HDAC inhibitors with the cytotoxic fluorouracil (5-FU) show

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.